Research programme: G protein-coupled receptor modulators - Domain Therapeutics/Pfizer
Latest Information Update: 28 May 2024
At a glance
- Originator Domain Therapeutics; Pfizer
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 May 2024 No recent reports of development identified for research development in Unspecified in France
- 28 May 2024 No recent reports of development identified for research development in Unspecified in USA
- 01 Sep 2020 Domain Therapeutics expands its collaboration agreement with Pfizer to co-develop G protein-coupled receptor modulators